Potentially inappropriate medications (PIMs): frequency and extent of GP-related variation in PIMs: a register-based cohort study

Anette Riisgaard Ribe, Line Due Christensen, Claus Høstrup Vestergaard, Anders Prior, Peter Krogh Brynningesen, Flemming Bro, Annelli Sandbæk, Peter Vedsted, Daniel R Witte, Morten Fenger-Gron

INTRODUCTION

Globally, the prevalence of multimorbidity, is expected to rise in the future. This development is due to improved diagnostics, enhanced survival and an ageing population. However, the complexity of managing multiple concurrent chronic conditions challenges modern healthcare. Multimorbidity may require polypharmaceutical treatment (>5 medications), and this holds a risk of both undertreatment and overtreatment. Potentially inappropriate medications (PIMs) can be defined as medications in which the risks of use are likely to outweigh the benefits, or safer alternatives exist, and PIMs can thus serve as a proxy for overtreatment. PIMs are common in older
individuals. The prevalence ranges from 21% to 79% in different healthcare contexts, such as hospitals and general practice, and PIMs may have serious consequences for the individual in terms of lower quality of life, higher risk of emergency visits and higher number of hospital admissions. Moreover, PIMs may generate substantial financial costs for both the individual and society. In Denmark, the general practitioners (GPs) handle over 80% of all prescription medications. They are central players in the management of chronic diseases and thus have a favourable position to assess the patient’s medications across diseases. Yet, evidence suggests that barriers to reducing PIMs exist. Furthermore, considerable variation has been reported for other treatment-related activities in general practice; this could indicate heterogeneous quality of the provided healthcare. Nevertheless, little is known on whether the prevalence of PIMs varies between GPs, and whether such potential variation may exceed the expected variation caused by differences in patient populations and by random variation. Such excess variation could be a marker of differences in the treatment strategies of the GPs and thus of suboptimal prescribing practices.

Using a coding algorithm to identify PIMs in the Danish nationwide registers, we aimed to explore the prevalence of PIMs and the GP-related variation in the prevalence of PIMs, while accounting for differences between practice populations and for the fact that some variation is expected due to randomness alone.

**METHODS**

**Setting and study population**

The study population included all persons aged ≥18 years who were listed with a Danish GP clinic and who had at least five consecutive years of residence in Denmark (to allow for the collection of register-based data in the 5 years preceding the inclusion). Eligible persons were followed from 1 January 2016 until death, emigration, exit from the GP listing system for other reasons, or 31 December 2016, whichever came first. We excluded GP clinics accumulating less than 500 patient years in 2016 (table 1, online supplemental material 1).

Denmark has free tax-funded healthcare, and more than 98% of the population are listed with a specific GP clinic, which serves as their primary entry point to the healthcare system and as a gatekeeper to specialised care. Around half of the Danish GP clinics are solo practices, around 40% of clinics consist of two–three GPs, and approximately 10% of clinics have more than three GPs.

**Data sources**

The project was carried out as a population-based cohort study using the nationwide Danish registers. We obtained data on sex, age, emigration and death from the Danish Civil Registration System, data on marital status, education, income and ethnicity from Statistics Denmark (Integrated Database for Longitudinal Labour Market Research), data on hospital diagnoses and procedure codes from the Danish National Patient Register, data on psychiatric hospital diagnoses from the Danish Psychiatric Central Research Register, data on redemption dates and redeemed volumes of prescribed medications classified according to the Anatomical Therapeutic Chemical Classification codes from the Danish National Prescription Register, and data on the link between the patient and the GP clinic from the Patient List Database. All data on diagnoses were obtained from public hospitals in Denmark, which must all report to the Danish National Patient Register. Private hospitals account for less than 1% of the total number of beds and do not provide acute care in Denmark. All of these data were linked at the individual level through the unique personal identification number provided by the Danish Civil Registration System, which also keeps track of vital status and migrations for all residents in Denmark.

**Identification of PIMs**

PIMs can be identified through the formal STOPP criteria for potentially inappropriate drugs, drug–drug combinations and drug–disease combinations that are included in the second version of the validated STOPP/START list, which was developed by O’Mahony and colleagues. In this study, we identified PIMs using a coding algorithm based on these STOPP criteria, which we adapted for a Danish register-based context through iterative consensus group discussions (see details in Supplemental methods, online supplemental material 1). This process led to the selection of 29 STOPP criteria, which could be operationalised for application in the Danish registers. Thus, 47 of the 76 STOPP criteria were excluded due to unavailable data (ie, laboratory measurements, procedures or diagnoses made in primary care, severity of diseases, dosage of medications and some specific medications), due to lack of clinical relevance (generally or in Denmark specifically) or due to overlap between criteria (in some cases, two criteria were collapsed into one after relevant modifications) (see coding details for the STOPP criteria in online supplemental material 2 and details on consensus modifications in online supplemental material 3).

After redeeming a prescription of a drug in any of the PIM categories, individuals were considered continuous ‘users’ of that drug for a period of time corresponding to the number of redeemed defined daily doses (DDD), that is, the assumed average maintenance dose per day for a drug used for its main indication in adults, plus a grace period of 25% to allow for some leeway when redeeming prescriptions. This period of use was extended each time a user redeemed a new prescription. For the PIM criteria defined by two concurrent treatments, some individuals were excluded during quarantine periods in-between treatments, as we could not distinguish between overlapping treatments and treatment shifts before the first prescription expired (see details in Supplemental methods, online supplemental material 1).
| STOOP criterion | Persons‡ at risk§ | Risk time§, years | Persons‡ with PIMs | PIM time, years (PIM rate¶, %) |
|----------------|------------------|------------------|-----------------|--------------------------|
| **B3:** Beta blocker combined with verapamil or diltiazem | 2443308 | 4 207 285.4 | 3090 | 1332.8 (0.0) |
| **B4:** Beta blocker combined with bradycardia or heart block | 25321 | 22010.0 | 10084 | 5113.8 (23.2) |
| **B5:** Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias | 50406 | 45528.7 | 1165 | 633.0 (1.4) |
| **B6:** Loop diuretic as first-line treatment for hypertension | 40440 | 34969.6 | 3800 | 2264.7 (6.5) |
| **B13:** Phosphodiesterase type-5 inhibitors in severe heart failure or concurrent nitrate therapy for angina | 69148 | 65115.3 | 3186 | 666.5 (1.0) |
| **C3:** Aspirin, clopidogrel, dipyridamole, vitamin K antagonists, direct thrombin inhibitors or factor Xa inhibitors with concurrent significant bleeding | 32829 | 25931.4 | 13136 | 8510.3 (32.8) |
| **C4:** Aspirin plus clopidogrel as secondary stroke prevention, unless the patient has had a coronary stent(s) inserted in the previous 12 months, concurrent acute coronary syndrome, or a high-grade symptomatic carotid arterial stenosis | 147722 | 138090.5 | 8149 | 3712.8 (2.7) |
| **C6:** Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients with stable coronary, cerebrovascular or peripheral arterial disease | 4243867 | 4 195 000.3 | 20428 | 8126.5 (0.2) |
| **C8:** Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first deep venous thrombosis without continuing provoking risk factors for >6 months | 39815 | 36658.6 | 3963 | 2532.4 (6.9) |
| **C9:** Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first pulmonary embolus without continuing provoking risk factors for >12 months | 12811 | 11218.6 | 2703 | 1675.5 (14.9) |
| **C10:** NSAID and vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in combination | 4244304 | 4 206 445.8 | 8904 | 2276.7 (0.1) |
| **D1:** Tricyclic antidepressants (TCAs) with dementia, narrow angle glaucoma, cardiac conduction abnormalities, prostatism or prior history of urinary retention | 85667 | 73481.5 | 2022 | 804.3 (1.1) |
| **D3:** Neuroleptics with moderate-marked anticholinergic effects with a history of prostatism, or previous urinary retention | 11605 | 3742.0 | 67 | 9.3 (0.2) |
| **D5:** Long-term use of benzodiazepines | 4244310 | 4 207 443.1 | 81621 | 48722.9 (1.2) |
| **D6:** Antipsychotics (ie, other than quetiapine or clozapine) in those with parkinsonism or Lewy body dementia | 10495 | 9711.0 | 849 | 303.9 (3.1) |
| **D8:** Anticholinergics in patients with delirium or dementia | 43757 | 36604.8 | 8493 | 4459.2 (12.2) |
| **D9:** Neuroleptic antipsychotic in patients with behavioural and psychological symptoms of dementia (BPSD) | 38832 | 34661.5 | 4624 | 786.7 (2.3) |
| **D11:** Acetylcholinesterase inhibitors with a known history of persistent bradycardia, heart block or recurrent unexplained syncope, or concurrent treatment with drugs that reduce heart rate | 12238 | 6478.4 | 3747 | 1808.1 (27.9) |
| **D12:** Phenothiazines as first-line treatment | 4156076 | 4 105 909.6 | 5047 | 729.5 (0.0) |
| **G1:** Theophylline as monotherapy for COPD | 4137262 | 4 005 654.4 | 581 | 251.5 (0.0) |
| **H6:** Long-term use of NSAIDs | 4244310 | 4,207,443.1 | 125945 | 51074.4 (1.2) |
| **H7:** COX-2 selective NSAIDs with concurrent cardiovascular disease | 391248 | 380518.5 | 360 | 96.1 (0.0) |
| **I1:** Antimuscarinic drugs with dementia, chronic cognitive impairment, narrow-angle glaucoma or chronic prostatism | 60600 | 46522.8 | 1928 | 1106.4 (2.4) |
| **I2:** Selective alpha-1 selective alpha blockers in those with symptomatic orthostatic hypotension or micturition syncope | 20535 | 6659.3 | 825 | 200.2 (3.0) |
| **J2:** Thiazolidenediones in patients with heart failure | 68932 | 65030.6 | 10 | 2.4 (0.0) |
**Table 1** Continued

| STOPP criterion                                      | Persons‡ at risk§ | Risk time§, years | Persons‡ with PIMs | PIM time, years (PIM rate¶, %) |
|------------------------------------------------------|-------------------|-------------------|-------------------|--------------------------------|
| **J4:** Oestrogens with a history of breast cancer or venous thromboembolism | 106975            | 104283.3          | 1727              | 1225.6 (1.2)                   |
| **J6:** Androgens in the absence of primary or secondary hypogonadism | 2079319           | 2 060 386.4       | 1774              | 1009.0 (0.0)                   |
| **K3:** Vasodilator drugs with persistent postural hypotension | 19534             | 5964.2            | 7504              | 1962.3 (32.9)                  |
| **M:** Concomitant use of ≥2 drugs with anticholinergic properties | 4244295           | 4 206 255.3       | 15986             | 6529.2 (0.2)                   |
| **Any PIM (unique persons and unique person time)†** | 4244310           | 4 207 443.1       | 294542            | 144 116.5 (3.4)                |

*PIMs were identified through our coding algorithm for selected STOPP criteria. The algorithm was modified in accordance with the STOPP/START criteria as developed by O’Mahony and colleagues and Huibers and colleagues.

†The measure ‘any PIM’ included unique individuals and unique PIM time only, which implied that individuals contributed only once with PIM time, even when having two or more concurrent PIMs. Thus, this measure estimated the time spent with at least one PIM.

‡The number of persons represented unique individuals.

§In some cases, the risk population (and their risk time of relevance) included all persons in the study population (ie, B3, C10, D5, H6 and M). Although the risk population for each of these criteria included all individuals, the criteria in which PIMs were defined by two or more concurrent treatments (ie, B3, C10 and M) had risk populations that differed slightly from the entire study population due to exclusion of individuals during the quarantine periods in-between treatments. In other cases, the risk population included only patients with a given condition or combination of conditions.

¶The PIM rate was calculated as the total time spent with PIM divided by the total time spent at risk.

NSAIDs, non-steroidal anti-inflammatory drugs; PIMs, potentially inappropriate medications.

**Additional covariates**

In addition to the specific medications and medical or psychiatric conditions mentioned in the criteria, all persons under study were characterised in terms of age, sex, cohabitation status, education, income and ethnicity (Appendix I, online supplemental appendix I, online supplemental material 1) as well as morbidity status according to a modified version of the Danish Multimorbidity Index (DMI), which included 36 physical and mental disorders identified from a combination of diagnosis and prescription data from the above-mentioned sources (online supplemental appendix II, online supplemental material 1).

**Statistical analyses**

For all PIM criteria, both overall and subgroup-specific crude counts of persons with PIMs were calculated as was the potential time spent with PIMs (PIM time). Furthermore, the PIM rates in the population for each of the criteria were calculated as the PIM time divided by the total time spent at risk (risk time), corresponding to the average proportion of the risk population (specific for the criterion in question) that was exposed to PIMs at a given time during the study period. In some cases, the risk population included all persons in the study population. In other cases, it included only persons with a given condition or combination of conditions.

The analyses of the GP-related variation involved several steps. First, a series of multivariate Poisson regressions were used to estimate the expected PIM time for each of the PIM criteria for all persons according to their covariate status and time at risk (included with the regression parameter restricted to 1). The expected total PIM time for each person was calculated as the sum of expected time with each criterion (0 for criteria that were irrelevant for the given person). Subsequently, these expected PIM times were compared with the observed PIM times for each person and aggregated for each GP clinic, allowing for the calculation of clinic-specific observed/expected ratios. For each criterion, these ratios were sorted and subsequently depicted graphically (in groups of five clinics to comply with data deidentification regulations) to describe the variation between clinics, and the 90th/10th percentile ratio (equaling the ratio between the highest vs the lowest quintile medians) was calculated as a measure of the ‘observed variation’. To assess the extent of variation in the GP clinic-specific observed/expected ratios that would be expectable even if no systematic/true differences between the GPs’ treatment strategies exist (ie, the anticipatable random variation), we calculated a ‘sampled variation’ by essentially repeating all of the above steps in a second round, in which the GP clinics were assigned reference populations of matched patients (from the same risk population) sampled from the other clinics. Matching was performed for persons of the same age and sex, who had the best match of estimated propensity for that specific PIM on 1 January 2016. The propensity score included information on cohabitation status, income, education, ethnicity and the 36 comorbidities included in the modified version of the DMI. Finally, we calculated the ‘excess variation’ as the ratio between the observed variation and the sampled variation. Thus, the excess variation represents a factor measure of the extent to which the observed variation exceeds the level of variation that could be expected.
due to chance alone; that is, the excess variation would be one if the observed variation did not exceed the expected random variation, whereas it would be equal to the observed variation in a (hypothetical) situation with no contribution from random variation. For PIM criteria with a 10th percentile equal to zero, excess variation was calculated as the ratio between the 90th percentiles alone to avoid division by zero.

The linear correlation between the observed/expected ratio for each of the criteria and the observed/expected ratio of the total PIM time (for each GP clinic) was measured by Pearson’s ρ.30 For this calculation, we used a jackknife approach, which implied subtraction of the contribution made by the given criterion from the overall score.

All analyses were performed in Stata V.16, College Station, TX.

Patient and public involvement
We analysed deidentified population-based healthcare register data. Patients were not involved in the development of the research question, the outcome measures or the study design. We plan to disseminate the results of the research to Danish GPs, the general public, and policy-makers.

RESULTS
The study population included a total of 4 214 510 unique individuals who were at risk of PIMs during 4 207 443 risk years in 2016; these individuals were distributed across 1906 clinics, that is, approximately 2200 patients per GP clinic (table 1). Here, 27% were older than 60 years of age, 51% were female and 17% had two or more comorbidities (figure 1, online supplemental material 1). However, 20 out of 29 criteria yielded risk populations with substantially higher ages and higher prevalence of multimorbidity (figure 1, online supplemental material 1).

Extent of PIMs
Overall, 294 542 unique individuals were exposed to 144 117 PIM years (ie, time spent with at least one PIM), which corresponded to a PIM incidence rate of 3.4% (table 1). The most prevalent PIM criteria were: B4 (ie, beta blocker with bradycardia or heart block) (5114 years), C3 (ie, aspirin, clopidogrel, dipridamolone, vitamin K antagonists, direct thrombin inhibitors or factor Xa inhibitors with concurrent significant bleeding risk) (8510 years), C6 (ie, antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors) (8127 years), D5 (ie, long-term use of benzodiazepines defined as use of more than 90 DDDs within 6 months) (48 723 years), D8 (ie, anticholinergics in patients with delirium or dementia) (4459 years), H6 (ie, long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) defined as use of more than 90 DDDs within 6 months) (51 074 years) and M (ie, concomitant use of two or more drugs

with anticholinergic properties) (6529 years) (table 1). Among these seven criteria with the highest prevalence, the PIM rate was 23.2% for B4, 32.8% for C3 and 12.2% for D8, but 0.2% to 1.2% for the remaining four criteria.

This was, however, explained by the fact that these criteria included (basically) all individuals from the study population in their risk populations (table 1).

Figure 1
Variation in the seven most prevalent PIM criteria and total PIMs in adults in 2016. Abbreviations: Observed/expected: observed/expected ratio of PIM time. Obs: observed variation in the actual GP populations (the 90th/10th percentile ratio of the observed/expected ratio of PIM time). Samp: sampled variation in the randomly sampled GP populations (the 90th/10th percentile ratio of the observed/expected ratio of PIM time). Excess: excess variation (the observed variation/sampled variation ratio). *Content for each of the criteria is detailed in Table 1. **Total PIMs represents the sum of all PIM time. Thus, persons can contribute with PIM time more than once if they have multiple PIMs at the same time. Therefore, the number of PIM years for this aggregated measure was different from the number in Table 1, which measured ‘any PIM’. In all other analyses, including in this figure, ‘total PIMs’ was measured.

GP-related variation in PIMs
Variation in total PIMs
Across GP clinics, a factor 2.18 variation in total PIMs was observed for the 90th/10th percentile ratio (‘observed variation’), whereas a factor 1.32 variation was expected due to random variation alone (‘sampled variation’), that is, if no true/systematic differences between GPs existed (figure 1 and table 2). This corresponded to a 1.65 times higher variation than expected when taking into account differences in patient characteristics and randomness alone (‘excess variation’) (figure 1 and table 2).

Variation in specific criteria
The observed variation was considerable for all criteria. However, only for a few cases, this variation was higher than what could be explained by differences in patient characteristics and randomness. Still, long-term use of NSAIDs, which was the most prevalent type of PIMs, showed an observed variation of 3.59 when differences
| Criterion* | Observed variation† | Sampled variation‡ | Excess variation (observed variation/sampled variation ratio)§ | Correlation Pearson’s ρ ¶ (p-value) |
|-----------|---------------------|-------------------|-------------------------------------------------|---------------------------------|
| B3        | 2.79/0 .** 2.51/0 . | 1.11              | 0.04 (0.124)                                      |                                 |
| B4        | 1.63/0.30 5.38      | 1.07              | 0.00 (0.982)                                      |                                 |
| B5        | 3.06/0 .            | 0.98              | 0.01 (0.779)                                      |                                 |
| B6        | 2.29/0 .            | 1.09              | 0.13 (<0.001)                                     |                                 |
| B13       | 2.74/0 .            | 1.05              | 0.05 (0.033)                                      |                                 |
| C3        | 1.49/0.50 2.99      | 1.09              | 0.01 (0.551)                                      |                                 |
| C4††      | 2.05/0.06 37.17     | 1.81              | 0.17 (<0.001)                                     |                                 |
| C6        | 1.70/0.30 5.72      | 1.53              | 0.06 (0.016)                                      |                                 |
| C8        | 2.17/0 .            | 0.99              | 0.02 (0.353)                                      |                                 |
| C9        | 2.25/0 .            | 1.01              | 0.03 (0.207)                                      |                                 |
| C10††     | 2.27/0.03 72.03     | 4.02              | 0.42 (<0.001)                                     |                                 |
| D1        | 2.89/0 .            | 1.02              | 0.02 (0.346)                                      |                                 |
| D3        | 0/0 .               | 0/0 .             |                                                 |                                 |
| D5        | 1.91/0.37 5.11      | 3.05              | 0.36 (<0.001)                                     |                                 |
| D6        | 2.96/0 .            | 0.99              | 0.03 (0.201)                                      |                                 |
| D8        | 1.86/0.12 15.25     | 1.25              | 0.06 (0.012)                                      |                                 |
| D9        | 2.39/0 .            | 0.98              | 0.05 (0.043)                                      |                                 |
| D11       | 2.09/0 .            | 0.98              | −0.01 (0.671)                                     |                                 |
| D12       | 2.85/0 .            | 1.06              | 0.09 (<0.001)                                     |                                 |
| G1        | 3.23/0 .            | 0.94              | 0.09 (<0.001)                                     |                                 |
| H6        | 1.64/0.46 3.59      | 2.33              | 0.45 (<0.001)                                     |                                 |
| H7        | 0.81/0 .            | 0.41              | 0.05 (0.024)                                      |                                 |
| I1        | 2.84/0 .            | 1.03              | 0.07 (0.002)                                      |                                 |
| I2        | 3.11/0 .            | 0.95              | 0.03 (0.156)                                      |                                 |
| J1        | 0/0 .               | 0/0 .             |                                                 |                                 |
| J4        | 2.89/0 .            | 1.05              | 0.11 (<0.001)                                     |                                 |
| J6        | 2.96/0 .            | 1.05              | 0.09 (<0.001)                                     |                                 |
| K3        | 1.69/0.28 6.04      | 0.58              | 0.03 (0.216)                                      |                                 |
| M         | 1.76/0.31 5.67      | 1.11              | 0.09 (<0.001)                                     |                                 |
| Total PIMs‡‡ | 1.44/0.66 2.18 | 1.65 | – |                               |

The bold values highlighted the observed variations and the excess variations.
*Content for each of the criteria is detailed in table 1.
†The observed variation measured the 90th/10th percentile ratio (of the observed/expected ratio of PIM time) in the studied GP populations (actual GP populations).
‡The sampled variation measured the 90th/10th percentile ratio (of the observed/expected ratio of PIM time) in the randomly sampled GP populations.
§To avoid division by zero, excess variation was calculated as the ratio between the 90th percentiles alone for the PIM criteria with 10th percentile equal to zero.
¶The linear correlation between the observed/expected ratio for each of the criteria and the observed/expected ratio of the total PIM time (for each GP clinic) was measured by Pearson’s ρ.
**Full stop denoted missing data.
††The observed variation for these criteria should be interpreted with caution, as the 10th percentiles were close to zero.
‡‡Total PIMs estimated a composite measure of all STOPP criteria (calculated by summing up observed and expected PIM time for each PIM criterion). The figure for total PIMs was 157 926 PIM years. All analyses on observed/expected PIM time were based on the total PIM measure.
GP, general practitioner; PIMs, potentially inappropriate medications.
in patient characteristics were taken into account, and the excess variation was 2.33 times higher than expected when randomness was also taken into account. Similarly, long-term use of benzodiazepines showed an observed variation of 5.11 and an excess variation of 3.05. Furthermore, the remaining five most prevalent criteria showed excess variations ranging from 1.07 to 1.53 (figure 1 and table 2).

The calculation of the 90th/10th percentile ratio (observed variation) was only feasible for three of the remaining criteria (C4, C10 and K3), as the denominator (10th percentile) was zero for the rest of the criteria. Although all three criteria showed substantial observed variation (C4: 37.17, C10: 72.03 and K3: 6.04), only C4 and C10 showed considerable excess variation when randomness was taken into account (ie, excess variation of 1.81 and 4.02, respectively) (figure 1 and table 2, online supplemental material 1).

For more than half of the criteria, we found a statistically significant positive correlation between the observed/expected ratio of total PIMs and the observed/expected ratio of total PIMs (table 2). Among the seven most prevalent criteria, such positive correlation was found for the five criteria with highest excess variation (C6: 0.06 (p-value: 0.016); D5: 0.36 (p-value:<0.001), D8: 0.06 (p-value: 0.012), H6: 0.45 (p-value:<0.001) and M: 0.09 (p-value:<0.001)) (table 2).

**DISCUSSION**

**Principal findings**

Almost 300,000 individuals were exposed to around 150,000 PIM years in 2016 in Denmark. The highest prevalence of PIMs was found for long-term use of NSAIDs and benzodiazepines, which accounted for approximately 50,000 PIM years each. The observed variation was substantial for virtually all criteria, although for a minority only, this variation was substantially higher than expected due to randomness. Yet, for more than half of the criteria, we observed a statistically significant positive correlation between the specific PIM and the sum of the remaining PIMs. Across GP clinics, we found an observed variation of 2.18, which exceeded the expected random variation by a factor 1.65. Long-term use of NSAIDs and long-term use of benzodiazepines showed the most pronounced variations, and this could not be explained by differences in patient characteristics or by randomness.

**Interpretation of results**

The substantial prevalence of certain PIMs might be explained by the existence of barriers for deprescribing PIMs caused by patient-related factors, provider-related factors and the organisational, structural and sociocultural context.13 31 32 Yet, the reasons for such barriers remain multifactorial; they are highly interdependent and are characterised by considerable clinical complexity.13 The patients’ strong belief in the necessity of their medications is often reported as a central barrier for deprescribing.33 Furthermore, GPs find it challenging to balance benefits and harms across treatments in patients with polypharmacy due to pharmacological complexity and lack of guidelines for multimorbidity.13 31 From an organisational point of view, time is a limited resource, and many GPs are short of time to prioritise comprehensive medication reviews.13 31 Structurally, some GPs point to the fragmented healthcare system and the unclear treatment responsibility as complicating barriers.31 From a sociocultural point of view, GPs report a hierarchy in which their professionalism is occasionally challenged by the specialist physicians, leading to avoidance of deprescribing medications initiated during hospital contact.32

Substantial PIM prevalence and GP-related variation in long-term use of benzodiazepines might be caused by complex interaction of drug, patient, physician and organisational barriers.34 Although recent systematic guidelines have concluded that deprescribing appears to be relatively safe and feasible; in the case of benzodiazepines, it is particularly challenging.35 First, psychological and physical dependence may compound the problem of inadequate patient adherence.35 Second, lack of equally effective alternatives to treat the patients’ insomnia or anxiety may play a role. Although the licensing of selective serotonin reuptake inhibitors for anxiety disorders and melatonin agonists for insomnia has allowed for therapeutic choices of prescribers,36 there is no convincing evidence to recommend substitution.35 Third, limited evidence exists on how to best conduct the process of deprescribing, although patient involvement and shared decision-making have been suggested to be important for facilitating deprescribing.35 36 Specifically, the optimal tapering schedule remains unknown.35 36

Similarly, the substantial prevalence of and variation seen for long-term use of NSAIDs might be explained by the fact that it is complicated to deprescribe NSAIDs as no safer and equally effective alternative analgesic exists.37

Apart from long-term use of benzodiazepines and NSAIDs, five other PIM criteria were common (B4, C3, C6, D8 and M). In some cases, this could partly be explained by large risk populations (C6 and M). In other cases, this could be explained by high rates (B4, C3 and D8), which are likely to be caused by significantly older populations with more multimorbidity; this entails higher degree of complexity in the clinical care and higher risk of overseeing needs for reducing medications.

Although the observed variation was substantial for virtually all PIM criteria, this variation did not substantially exceed what could be expected due to random variation for the majority of the studied criteria. Hence, these criteria cannot be used as independent performance measures of the GP clinics. Nevertheless, more than half of the studied criteria had a statistically significant positive correlation to the sum of remaining PIMs. This suggests that the majority of the criteria constitute markers of an underlying GP-related variation in prescribing strategy and may thus contribute with relevant information to the aggregate measure of total PIM time.
Comparison with other studies

Over the past decades, it has been increasingly recognised that the variations in the use of healthcare services, for example, between geographical areas, periods or organisational units like GP clinics, are often higher than expected based on the health status of the population. Few studies have explored the GP-related variation in the prescribing of PIMs, high-risk prescribing, polypharmacy and overall prescribing, but they only take into account differences in the characteristics of the GP-clinics or of the patient population when concluding that the observed variation is a marker of inefficient or inappropriate prescribing. This approach is likely to overestimate the variation and thus to overestimate the extent of suboptimal GP prescribing. To the best of our knowledge, our study is the first to describe GP-related variations in PIMs, while accounting for differences between GP populations and for the fact that some degree of variation is to be expected due to randomness.

Strengths and weaknesses of the study

This study has several strengths, including the large data set, complete follow-up and the population-based setting, in which more than 4 million adults were followed essentially without loss to follow-up. This practically eliminated the risk of selection bias and allowed for the identification of even rare PIM outcomes. Furthermore, a couple of aspects of the analysis approach deserve mentioning, as these facilitated the estimation of the GP-related variation in PIMs, which could be interpreted as a marker of suboptimal treatment performance. First, we had comprehensive high-quality data at the patient level. This allowed for thorough matching and adjustments, which took into account in-between GP differences in the patient characteristics. This enabled us to characterise the GP-clinics by qualified observed/expected ratios rather than by crude frequency measures. Second, we applied a matching/sampling procedure to quantify the extent of variation, which could be expected to be due to randomness alone, and used this as a reference for the observed variation. Noteworthy, without these approaches, the GP-related variation would have been grossly overestimated, as we demonstrated that although the observed variation was substantial, for the majority of criteria, this variation did not exceed that expected due to randomness.

However, some important limitations pertain to this study. First, the perception of PIMs as markers of suboptimal treatment quality does not necessarily hold true in all cases. Although each of the PIM criteria certainly represents ‘a red flag’ for the prescriber, some PIMs may be the best treatment option for certain patients if administered with care, such as those who do not fit the guidelines (eg, frail patients with high complexity of diseases for whom there may be a need for balancing conflicting demands). Yet, exact identification of these patient would require more detailed clinical information than available from the registers. However, as we were able to characterise the study participants comprehensively, allowing for an extensive patient profiling, we find it reasonable to assume that additional characteristics, such as frailty measures, are randomly distributed across the GP clinics. This implies that the considerable excess variation, as calculated in this paper, is likely, at least to some degree, to be a marker of uneven and thus suboptimal GP performance. Second, although the excess variation is a valuable marker of the existence of ‘true variation’ in GP performance, it may be a highly conservative measure. The sampled variation quantifies the inflation of the observed variation that should be expected due to randomness under the null hypothesis (ie, if no true differences between GP clinics exist). However, if the true between-GP variation is non-null, the inflation due to random noise could be lower or even negative. Third, we studied GP clinics as the unit of variation, which may entail that we have underestimated the variation in-between GPs, although it is likely that GPs in the same clinic have reasonably homogeneous prescribing preferences. Fourth, some data were not available, including data on laboratory measurements, clinical observations (eg, blood pressure profiles), untreated diagnoses exclusively managed in primary care (eg, alcohol abuse), disease severity measures, measures of frailty, estimated life expectancy, medication adherence, over-the-counter medications, medications administered during in-patient hospitalisations and some of the medication data. This had several implications. Primarily, we cannot exclude residual confounding, which could have impacted our findings in either direction. Furthermore, leaving non-codeable elements out of the algorithm led to the simplification of certain criteria. Finally, the lack of information on over-the-counter NSAIDs might imply that the use of these drugs could be underestimated. Fifth, we used the original Irish STOPP/START criteria and modified these for a Danish register-based setting. This could have reduced the generalisability, as some countries may rely on other local versions of these criteria and adhere to slightly different clinical guidelines. Yet, by providing our coding algorithms, this algorithm can easily be adapted for application in other settings.

CONCLUSION

Clinical implications

We identified long-term use of NSAIDs and benzodiazepines as the most prevalent PIMs with the most pronounced GP-related variations. Furthermore, our study suggests that prescribing certain types of PIMs is a marker of prescribing other PIMs. Our findings allow for the interpretation that some PIMs, such as long-term use of NSAIDs and benzodiazepines, seem to mark suboptimal GP-prescribing and targeting the use of these drugs may be a reasonable place to start in the conduct of future intervention studies. These PIMs both had a high prevalence, making such intervention clinically relevant and a substantial excess variation, suggesting room for improvements.
Future research
This study highlights the need for exploring the causal explanations for the substantial prevalence and the related variations in the treatment strategies of GPs for certain PIMs, such as long-term use of NSAID and benzodiazepines, which could represent obvious targets for future interventions aimed at reducing PIMs. Moreover, our register-based algorithm for measuring PIMs can be applied in future interventions aimed at optimising GP prescribing behaviour, including selecting patients with the greatest need for special efforts and assessing the effectiveness of the intervention.

Acknowledgements
The authors would like to thank Lone Niedziella, Research Unit for General Practice in Aarhus, for language editing and Dr Simon Winther, Department of Cardiology, Regional Hospital West Jutland, Herning, Denmark, for reviewing key criteria in the field of cardiology.

Contributors
ARR, MF-G, LDC, AP and FB conceived the study. ARR, MF-G, LDC, AP and CHV planned the study and developed the register-based algorithm for identifying PIMs. CHV and MF-G carried out the analyses. PKB reviewed the algorithm for consistency with existing clinical guidelines. AS and PV obtained the data. FB, ARR, MF-G and AP achieved the funding. ARR and LDC wrote the first draft of the manuscript. ARR, LDC, MF-G, CHV, AP, FB, PKB, AS, PV and DRW interpreted the results, revised the manuscript and approved the final version. ARR is the guarantor.

Funding
This study was supported by grants from the Novo Nordisk Foundation donated to ARR and AP (NNF16000010952 and NNF1800031194) and from the General Practice Research Foundation of the Central Denmark Region to MFG. All authors are independent from the funders, and the funders had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report or in the decision to submit the article for publication.

Competing interests
None declared.

Patient consent for publication
Not required.

Ethics approval
This project was approved by the Danish Data Protection Agency, the Danish Health Data Authority and Statistics Denmark. According to Danish legislation, ethical approval and informed consent were not needed as the study was entirely register-based.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
No data are available. Data not available due to legal restrictions.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Anette Riisgaard Ribe http://orcid.org/0000-0003-0011-2208
Anders Prior http://orcid.org/0000-0003-4053-3701

REFERENCES
1. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012;380:37–43.
2. Boyd CM, Fortin M. Future of multimorbidity research: how should understanding of multimorbidity inform health system design? Public Health Rev 2010;32:451–74.
3. Sinnige J, Braspennin JC, Schellevis FG, et al. Inter-practice variation in polypharmacy prevalence among older patients in primary care. Pharmacoeconomics Drug Saf 2016;25:1033–41.
4. Cahir C, Fahey T, Teeling M, et al. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol 2010;69:543–52.
5. Beers MH, Institute for Healthcare Improvement, Rocklingh I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA division of geriatric medicine. Arch Intern Med 1991;151:1825–32.
6. Rankin A, Cadogan CA, Patterson SM, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev 2018;9:Cd000816.
7. Corsonello A, Onder G, Abbatessa AC, et al. Explicit criteria for potentially inappropriate medications to reduce the risk of adverse drug reactions in elderly people: from beers to STOPP/START criteria. Drug Saf 2012;35 Suppl 1:1–8.
8. Moriarty F, Bennett K, Cahir C, et al. Potentially inappropriate prescribing according to STOPP and start and avoid outcomes in community-dwelling older people: a prospective cohort study. Br J Clin Pharmacol 2016;82:849–57.
9. Hedena K, Hakkarainen KM, Yllysten H, et al. Potentially inappropriate prescribing and adverse drug reactions in the elderly: a population-based study. Eur J Clin Pharmacol 2015;71:1525–33.
10. Hill-Taylor B, Skejta I, Hayden J, et al. Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. J Clin Pharm Ther 2013;38:360–72.
11. Cahir C, Bennett K, Teljeur C, et al. Potentially inappropriate prescribing and adverse health outcomes in community-dwelling older patients. Br J Clin Pharmacol 2014;77:201–10.
12. Vass M, Hendriksen C. Polypharmacy and older people—the GP perspective. Z Gerontol Geriatr 2005;38 Suppl 1:114–17.
13. Anderson K, Stowasser D, Freeman C, et al. Prescriber barriers and enables to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open 2014;4:e006544.
14. Hjertholm P, Fenger-Gron M, Vestergaard M, et al. Variation in general practice prostate-specific antigen testing and prostate cancer outcomes: an ecological study. Int J Cancer 2015;136:435–42.
15. Fenger-Gron M, Kjaersgaard MIS, Parner ET, et al. Early treatment with talk therapy or antidepressants in severely bereaved people and risk of suicidal behavior and psychiatric illness: an instrumental variable analysis. Clin Epidemiol 2018;10:1034–26.
16. Pedersen KM, Andersen JS, Søndergaard J. General practice and primary health care in Denmark. J Am Board Fam Med 2012;25 Suppl 1:S34–8.
17. Nørreke KB, Pedersen AF, Bro F, et al. Mental well-being and job satisfaction among general practitioners: a nationwide cross-sectional survey in Denmark. BMC Fam Pract 2018;19:130.
18. Erdangon A, Fedyuszyn I. Danish nationwide registers for public health and health-related research. Scand J Public Health 2015;43:333–9.
19. Schmidt M, Pedersen L, Sørensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol 2014;29:541–9.
20. Denmark S. The integrated database for longitudinal labour market research (Integreet database for arbejdsmarkedsforskning (IDAI)), 1991.
21. Schmidt M, Schmidt SAU, Sandegaard JL, et al. The Danish national patient registry: a review of content, data quality, and research potential. Clin Epidemiol 2015;7:449–99.
22. Mors O, Perto GP, Mortensen PB. The Danish psychiatric central research register. Scand J Public Health 2011;39:54–7.
23. Kildemoes HW, Sørensen HT, Hallas J. The Danish national prescription registry. Scand J Public Health 2011;39:38–41.
24. Pedersen KM, Christiansen T, Bech M. The Danish health care system: evolution - not revolution - in a decentralized system. Health Econ 2005;14:S41–57.
25. Pedersen CB. The Danish civil registration system. Scand J Public Health 2011;39:22–5.
26. O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 2015;44:213–8.
27. Halbers CJA, Sallieveld BTGM, de Groot DA, et al. Conversion of STOPP/START version 2 into coded algorithms for software implementation: a multidisciplinary consensus procedure. Int J Med Inform 2019;125:110–7.
28 Lund JL, Richardson DB, Stürmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. *Curr Epidemiol Rep* 2015;2:221–8.

29 Prior A, Fenger-Grøn M, Larsen KK, et al. The association between perceived stress and mortality among people with multimorbidity: a prospective population-based cohort study. *Am J Epidemiol* 2016;184:199–210.

30 Rodgers JL, Nicewander WA. Thirteen ways to look at the correlation coefficient. *Am Stat* 1988;42:59–66.

31 Sinnott C, Mc Hugh S, Browne J, et al. Gps’ perspectives on the management of patients with multimorbidity: systematic review and synthesis of qualitative research. *BMJ Open* 2013;3:e003610.

32 Laursen J, Kornholt J, Betzer C, et al. General practitioners’ barriers toward medication reviews in Polymedicated Multimorbid patients: how can a focus on the pharmacotherapy in an outpatient clinic support GPs? *Health Serv Res Manag Epidemiol* 2018;5:233392818792169.

33 Clyne B, Cooper JA, Boland F, et al. Beliefs about prescribed medication among older patients with polypharmacy: a mixed methods study in primary care. *Br J Gen Pract* 2017;67:e507–18.

34 Ng BJ, Le Couteur DG, Hilmer SN. Describing benzodiazepines in older patients: impact of interventions targeting physicians, pharmacists, and patients. *Drugs Aging* 2018;35:493–521.

35 Lee JY, Farrell B, Holbrook AM. Deprescribing benzodiazepine receptor agonists taken for insomnia: a review and key messages from practice guidelines. *Pol Arch Intern Med* 2019;129:43–9.

36 Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. *CNS Drugs* 2009;23:19–34.

37 Ong CKS, Lirk P, Tan CH, et al. An evidence-based update on nonsteroidal anti-inflammatory drugs. *Clin Med Res* 2007;5:19–34.

38 Wennberg JE. Unwarranted variations in healthcare delivery: implications for academic medical centres. *BMJ* 2002;325:961–4.

39 Brownlee S, Chalkidou K, Doust J, et al. Evidence for overuse of medical services around the world. *Lancet* 2017;390:156–68.

40 Fisher ES, Wennberg DE, Stukel TA, et al. The implications of regional variations in Medicare spending. Part 1: the content, quality, and accessibility of care. *Ann Intern Med* 2003;138:273–87.

41 Byrne CJ, Cahir C, Curran C, et al. Prescriber variation in potentially inappropriate prescribing in older populations in Ireland. *BMC Fam Pract* 2014;15:59.

42 Br J Clin Pharmacol 2017;83:2821–30.

43 Guthrie B, McCowan C, Davey P, et al. High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. *BMJ* 2011;342:d3514.

44 Stocks SJ, Kontopantelis E, Akbarov A, et al. Examining variations in prescribing safety in UK general practice: cross sectional study using the clinical practice research Datalink. *BMJ* 2015;351:h5501.

45 Ong SM, Lim YMF, Sivasampu S, et al. Variation of polypharmacy in older primary care attenders occurs at prescriber level. *BMC Geriatr* 2018;18:59.

46 et alDuerden M, Millson D, Avery A. The quality of GP prescribing: the kings fund, 2011. Available: https://www.kingsfund.org.uk/sites/default/files/field_document/quality-gp-prescribing-gp-inquiry-research-paper-mar11.pdf [Accessed 27 Oct 2020].

47 Christensen LD, Petersen J, Andersen O, et al. Physicians’ Non-Uniform Approach to Prescribing Drugs to Older Patients - A Qualitative Study. *Basic Clin Pharmacol Toxicol* 2017;121:505–11.